JP2020512302A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512302A5
JP2020512302A5 JP2019545923A JP2019545923A JP2020512302A5 JP 2020512302 A5 JP2020512302 A5 JP 2020512302A5 JP 2019545923 A JP2019545923 A JP 2019545923A JP 2019545923 A JP2019545923 A JP 2019545923A JP 2020512302 A5 JP2020512302 A5 JP 2020512302A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound according
alkyl
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019545923A
Other languages
English (en)
Japanese (ja)
Other versions
JP7152408B2 (ja
JP2020512302A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/051579 external-priority patent/WO2018163131A1/en
Publication of JP2020512302A publication Critical patent/JP2020512302A/ja
Publication of JP2020512302A5 publication Critical patent/JP2020512302A5/ja
Priority to JP2022155899A priority Critical patent/JP7381684B2/ja
Application granted granted Critical
Publication of JP7152408B2 publication Critical patent/JP7152408B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019545923A 2017-03-10 2018-03-10 遊離可能コンジュゲート Active JP7152408B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022155899A JP7381684B2 (ja) 2017-03-10 2022-09-29 遊離可能コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762469989P 2017-03-10 2017-03-10
US62/469,989 2017-03-10
US201762564820P 2017-09-28 2017-09-28
US62/564,820 2017-09-28
PCT/IB2018/051579 WO2018163131A1 (en) 2017-03-10 2018-03-10 Releasable conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022155899A Division JP7381684B2 (ja) 2017-03-10 2022-09-29 遊離可能コンジュゲート

Publications (3)

Publication Number Publication Date
JP2020512302A JP2020512302A (ja) 2020-04-23
JP2020512302A5 true JP2020512302A5 (enExample) 2021-04-22
JP7152408B2 JP7152408B2 (ja) 2022-10-12

Family

ID=61764062

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019545923A Active JP7152408B2 (ja) 2017-03-10 2018-03-10 遊離可能コンジュゲート
JP2022155899A Active JP7381684B2 (ja) 2017-03-10 2022-09-29 遊離可能コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022155899A Active JP7381684B2 (ja) 2017-03-10 2022-09-29 遊離可能コンジュゲート

Country Status (11)

Country Link
US (2) US11786599B2 (enExample)
EP (2) EP3592393B1 (enExample)
JP (2) JP7152408B2 (enExample)
KR (1) KR20190125310A (enExample)
CN (1) CN110545850A (enExample)
AU (2) AU2018231832A1 (enExample)
BR (1) BR112019017103A2 (enExample)
CA (1) CA3051173A1 (enExample)
DK (1) DK3592393T3 (enExample)
SI (1) SI3592393T1 (enExample)
WO (1) WO2018163131A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3592393T1 (sl) * 2017-03-10 2022-04-29 Quiapeg Pharmaceuticals Ab Sprostljivi konjugati
TW202003044A (zh) 2018-03-09 2020-01-16 瑞典商奎亞培格製藥公司 可釋放之抗體結合物
AU2019340472A1 (en) 2018-09-12 2021-04-01 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
CN111175387B (zh) * 2018-11-13 2022-06-07 成都康弘药业集团股份有限公司 一种米那普仑异构体的检测方法
US10768173B1 (en) 2019-09-06 2020-09-08 Element Biosciences, Inc. Multivalent binding composition for nucleic acid analysis
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
US11287422B2 (en) 2019-09-23 2022-03-29 Element Biosciences, Inc. Multivalent binding composition for nucleic acid analysis
KR102398574B1 (ko) 2019-10-10 2022-05-13 주식회사 엘지에너지솔루션 전지 모듈 및 이를 포함하는 전지 팩
CN110946844A (zh) * 2019-12-11 2020-04-03 正大制药（青岛）有限公司 一种含有艾地骨化醇的复方控释制剂
WO2021155427A1 (en) * 2020-02-03 2021-08-12 Snoretox Pty Ltd Composition and method
CN113456824B (zh) * 2020-03-31 2023-03-31 四川大学华西医院 一种抗肿瘤载药纳米复合材料
AU2021319863A1 (en) 2020-08-05 2023-02-16 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
CN112138170B (zh) * 2020-09-28 2022-05-20 广东药科大学 一种预防顺铂药源性聋的缀合物及其制备方法和应用
CN112316156B (zh) * 2020-10-27 2022-03-15 四川大学 具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
CN112402620A (zh) * 2020-12-07 2021-02-26 南开大学 肿瘤微环境还原响应性的纳米药物及其制备方法
CN112457383B (zh) * 2020-12-16 2022-06-17 阿南达 一种多肽、制备方法及其医药用途
CN112516285B (zh) * 2020-12-18 2022-09-02 中南大学 一种预防或治疗缺血/再灌注损伤的药物组合物及应用
CN112574272B (zh) * 2020-12-25 2021-09-21 中国医学科学院药用植物研究所 一种灵芝酸a衍生物的制备及其应用
WO2022166720A1 (zh) * 2021-02-05 2022-08-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
CN112999196B (zh) * 2021-03-03 2023-04-28 西安医学院 用于长效稳定释放的吗替麦考酚酯纳米制剂及其制备方法
CN113133989B (zh) * 2021-03-09 2023-04-25 西安医学院 一种用于抗结核药物利福平的长效制剂及制备方法
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物
CN114886817B (zh) * 2022-06-02 2023-06-27 杭州配方师科技有限公司 一种弗来歇氏柳叶菜和酵母菌锌发酵复合物、制备方法及应用
WO2023244517A1 (en) * 2022-06-16 2023-12-21 Merck Sharp & Dohme Llc Interleukin-2 prodrugs
CN116333047A (zh) * 2022-12-22 2023-06-27 四川大学华西医院 一种抗菌肽及其制备方法
CN119331240A (zh) * 2023-07-19 2025-01-21 南京大学 一种苯并环辛炔-聚乙二醇修饰的常山酮及其制备方法和应用
KR102623104B1 (ko) * 2023-08-23 2024-01-11 에프아이씨씨주식회사 보툴리눔톡신 결합체와 줄기세포 엑소좀 복합체를 유효성분으로 함유하는 피부 재생 및 주름 개선용 화장료 조성물 및 그의 제조 방법
WO2025257419A1 (en) * 2024-06-13 2025-12-18 4Moving Biotech Glp-1 receptor agonist compounds for treating a proliferative synovial disorder
CN118415977B (zh) * 2024-07-03 2024-08-23 山东新时代药业有限公司 一种米力农注射剂及其用途
CN119709677B (zh) * 2024-10-28 2025-05-06 皖西学院 一种糖基转移酶及其在制备金线莲苷中的应用
CN119613558B (zh) * 2024-12-12 2025-08-15 东北农业大学 一种抗磺胺嘧啶纳米抗体及其应用
CN120531651B (zh) * 2025-07-29 2025-09-30 清枫链食苏打饮品(吉林)有限公司 人参提取物、制备方法及其在美白嫩肤祛皱产品中的应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200130A (en) * 1878-02-12 Improvement in joining sheet metal to wire-cloth for the construction of fly-traps
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
WO1996012697A2 (en) 1994-10-21 1996-05-02 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US5830600A (en) * 1996-05-24 1998-11-03 Sri International Nonflammable/self-extinguishing electrolytes for batteries
JPH10175987A (ja) 1996-12-13 1998-06-30 Nof Corp 重合性基含有有機リン酸エステル化合物およびその製造方法
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5922897A (en) 1998-05-29 1999-07-13 Xerox Corporation Surfactant processes
JP2000212191A (ja) * 1999-01-26 2000-08-02 Sankyo Co Ltd リン酸誘導体
WO2002044196A1 (en) 2000-11-28 2002-06-06 University Of Massachusetts Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of rna
US6320041B1 (en) 2001-04-13 2001-11-20 Trilink Biotechnologies, Inc. Pre-activated carbonyl linkers for the modification of oligonucleotides
US6743905B2 (en) 2001-04-16 2004-06-01 Applera Corporation Mobility-modified nucleobase polymers and methods of using same
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20100240730A1 (en) 2002-02-20 2010-09-23 Merck Sharp And Dohme Corp. RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CA2515889C (en) 2003-02-14 2015-07-14 Quanta Biodesign, Ltd. The selective and specific preparation of discrete peg compounds
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US20070276139A1 (en) 2004-02-10 2007-11-29 Quanlai Song Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis
EP2087910B1 (en) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Polymeric prodrugs
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US20060063147A1 (en) 2004-09-21 2006-03-23 Chernov Boris K Omega-amino-PEG-phosphoramidites and conjugates thereof
TW200612993A (en) 2004-10-08 2006-05-01 Alza Corp Lipopolymer conjugates
EP1937294A4 (en) 2005-10-21 2009-11-04 Synageva Biopharma Corp GLYCOLIC AND GLYCOSYLATED THERAPEUTIC PROTEINS DERIVED FROM POULTRY
US8043833B2 (en) 2005-10-31 2011-10-25 Novo Nordisk A/S Expression of soluble therapeutic proteins
WO2007059912A1 (en) 2005-11-23 2007-05-31 Roche Diagnostics Gmbh Polynucleotide labelling reagent
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
JP5140824B2 (ja) * 2006-04-19 2013-02-13 国立大学法人 東京大学 リゾホスファチジルスレオニンおよびその誘導体
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2008067127A2 (en) 2006-11-09 2008-06-05 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN102149749B (zh) 2008-07-10 2014-06-25 塞瑞纳治疗公司 具有惰性端基的聚噁唑啉、由被保护的引发基团制备的聚噁唑啉以及相关化合物
EP2334334A1 (en) 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of nesiritide peptides
HRP20220057T1 (hr) 2009-05-20 2022-04-15 Biomarin Pharmaceutical Inc. Varijante natriuretičnog peptida c-tipa
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
DK2566335T3 (en) 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
EP2600897A2 (en) 2010-08-06 2013-06-12 The Regents of the University of Colorado, A Body Corporate Methods and compositions for the inhibition of fructokinase
CA2821411C (en) 2010-12-13 2020-02-25 Marek Kwiatkowski Functionalized polymers
BR112014001244A2 (pt) * 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
CA2843506C (en) 2011-08-12 2020-05-12 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013186632A2 (en) 2012-06-12 2013-12-19 Quiapeg Ab Conjugates of biologically active molecules to functionalized polymers
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
US11116847B2 (en) * 2013-12-19 2021-09-14 Seagen Inc. Methylene carbamate linkers for use with targeted-drug conjugates
KR20170063507A (ko) 2014-06-20 2017-06-08 어브게노믹스 인터내셔널 인코포레이티드 Her2 항체-약물 접합체
JP6369721B2 (ja) * 2014-07-04 2018-08-08 国立大学法人 東京大学 リゾホスファチジルセリン誘導体
CN104725628B (zh) * 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
MX2017008915A (es) 2015-01-09 2018-04-26 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp).
US10780179B2 (en) 2015-03-18 2020-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
WO2017031034A2 (en) 2015-08-14 2017-02-23 Rc Biotechnologies, Inc. Covalent linkers in antibody-drug conjugates and methods of making and using the same
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
SMT202200466T1 (it) 2016-01-08 2023-01-13 Ascendis Pharma Growth Disorders As Profarmaci di cnp con legame a supporto in corrispondenza del raggruppamento ciclico
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
SI3592393T1 (sl) * 2017-03-10 2022-04-29 Quiapeg Pharmaceuticals Ab Sprostljivi konjugati
TW202003044A (zh) 2018-03-09 2020-01-16 瑞典商奎亞培格製藥公司 可釋放之抗體結合物
AU2019340472A1 (en) * 2018-09-12 2021-04-01 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates

Similar Documents

Publication Publication Date Title
JP2020512302A5 (enExample)
US11629125B2 (en) Elimination of hepatitis b virus with antiviral agents
JP2015504650A5 (enExample)
ES2963716T3 (es) Profármacos de nucleósido fosforamidato
JP2007534636A5 (enExample)
TW201819384A (zh) 經取代吡<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 d10999.TIF" img-content="tif" orientation="portrait" inline="yes"></img>化合物及其用途
JP2020521740A5 (enExample)
JP2006524669A5 (enExample)
JP7710215B2 (ja) ピロール化合物
JP2017518959A5 (enExample)
JP7648528B2 (ja) モノマーおよびマルチマー抗ｈｂｖ薬
RU2016122908A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP2016533761A5 (enExample)
JP2016502519A (ja) Ｈｂｖ集合エフェクターの代替的使用
JP2007505138A5 (enExample)
JP2005526857A5 (enExample)
WO2014182643A2 (en) Methods for treating hcv infection
JP2006509842A5 (enExample)
JP2001335593A5 (enExample)
JPWO2020167984A5 (enExample)
EA041357B1 (ru) Противовирусные соединения для элиминации вируса гепатита b
JPWO2020210711A5 (enExample)